Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong · Delayed Price · Currency is HKD 4.370
-0.570 (-11.54%)
Feb 13, 2026, 4:08 PM HKT
Jiangsu Recbio Technology Revenue
Jiangsu Recbio Technology had revenue of 19.73M CNY in the half year ending June 30, 2025, with 329.17% growth. This brings the company's revenue in the last twelve months to 29.11M, down -32.92% year-over-year. In the year 2024, Jiangsu Recbio Technology had annual revenue of 27.01M, down -11.10%.
Revenue (ttm)
29.11M CNY
Revenue Growth
-32.92%
P/S Ratio
95.51
Revenue / Employee
57.42K CNY
Employees
507
Market Cap
3.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.01M | -3.37M | -11.10% |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | 1.46M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| BioDlink International Company | 1.17B |
| Medtide | 546.29M |
| Mabpharm | 464.53M |
| Qyuns Therapeutics | 351.04M |
| Antengene Corporation | 92.43M |